The onset and time course of response of negative symptoms to add-on fluvoxamine treatment

International Clinical Psychopharmacology

Volumn 18, Issue 2, 2003, Pages 87-92

  Silver, Henry ^a,b   Nassar, Ahmed ^c   Aharon, Nelson ^c   Kaplan, Alla ^c  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^c Western Galilee Mental Health Clinics   (Israel)

Author keywords

Fluvoxamine; Negative symptoms; Onset of response; Response analysis; Schizophrenia

Indexed keywords

FLUVOXAMINE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEGATIVE SYNDROME; PRIORITY JOURNAL; REGRESSION ANALYSIS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; APHASIA; CHRONIC DISEASE; CLINICAL TRIALS; DATA INTERPRETATION, STATISTICAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FLUVOXAMINE; HUMANS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 0037345841     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200303000-00004     Document Type: Article

References (31)

1. Andreasen NC (1983) Scale for the Assessment of Positive Symptoms (SAPS). Iowa City: University of Iowa.
2. Andreasen NC (1984) Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa.
3. Andreasen NC, Arndt S, Miller D, Flaum M, Nopoulos P (1995) Correlational studies of the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Positive Symptoms: an overview and update. Psychopathology 28:7-17.
4. Brebion G, Gorman JM, Malaspina D, Sharif Z, Amador X (2001) Clinical and cognitive factors associated with verbal memory task performance in patients with schizophrenia. Am J Psychiatry 158:758-764.
5. Carpenter WT, Jr, Kirkpatrick B (1988) The heterogeneity of the long-term course of schizophrenia. Schizophr Bull 14:645-652.
6. Carpenter WT, Heinrichs DW, Wagman AMI (1988) Deficit and non deficit forms of schizophrenia. Am J Psychiatry 145:578-583.
7. Czobor P, Bitter I, Volavka J (1991) Relationship between the Brief Psychiatric Rating Scale and the Scale for the Assessment of Negative Symptoms: a study of their correlation and redundancy. Psychiatry Res 36:129-139.
8. Dantchev N, Widlocher DJ (1998) The measurement of retardation in depression. J Clin Psychiatry 59(suppl 14):19-25.
9. Fenton WS, McGlashan TH (1992) Testing systems for assessment of negative symptoms in schizophrenia. Arch Gen Psychiatry 49:179-184.
10. Garver DL, Holcomb JA, Christensen JD (2000) Heterogeneity of response to antipsychotics from multiple disorders in the schizophrenia spectrum. J Clin Psychiatry 61:964-972.
11. Hamilton M (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
12. Herbener ES, Harrow M (2001) Longitudinal assessment of negative symptoms in schizophrenia/schizoaffective patients, other psychotic patients, and depressed patients. Schizophr Bull 27:527-537.
13. Hoffmann GM, Gonze JC, Mendlewicz J (1985) Speech pause time as a method for the evaluation of psychomotor retardation in depressive illness. Br J Psychiatry 146:535-538.
14. Kelley ME, van Kammen DP, Allen DN (1999) Empirical validation of primary negative symptoms: independence from effects of medication and psychosis. Am J Psychiatry 156:406-411.
15. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT, Jr (1989) The Schedule for the Deficit syndrome: an instrument for research in schizophrenia. Psychiatry Res 30:119-123.
16. Liddle PF, Morris DL (1991) Schizophrenic syndromes and frontal lobe performance. Br J Psychiatry 158:340-345.
17. Overall JE, Gorham DR (1962) The brief psychiatric rating scale (BPRS). Psychol Rep 10:799-812.
18. Silver H (2001) Fluvoxamine as an adjunctive agent in schizophrenia. CNS Drug Rev 7:283-304.
19. Silver H, Nassar A (1992) Fluvoxamine improves negative symptoms in treated chronic schizophrenia. An add on double blind placebo controlled study. Biol Psychiatry 31:698-704.
20. Silver H, Shmugliakov N (1998) Augmentation with fluvoxamine but not maprotiline improves negative symptoms in treated schizophrenia. J Clin Psychopharmacol 18:208-211.
21. Silver H, Barash I, Aharon N, Kaplan A, Poyurovsky M (2000) Fluvoxamine augmentation of antipsychotics improves negative symptoms in psychotic chronic schizophrenic patients: a placebo-controlled study. Int Clin Psychopharmacol 15:257-261.
22. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
23. Siris S (1991) Diagnosis of secondary depression in schizophrenia: implications for DSM-IV. Schizophr Bull 17:75-97.
24. Siris SG (1993) Adjunctive medication in the maintenance treatment of schizophrenia and its conceptual implications. Br J Psychiatry 163(suppl 22):66-78.
25. Sommers A (1985) 'Negative symptoms': conceptual and methodological problems. Schizophr Bull 11:364-379.
26. Strauss JS, Carpenter WJ, Bartko JJ (1974) The diagnosis and understanding of schizophrenia part 3: speculations on the processes that underlie schizophrenic symptoms and signs. Schizophr Bull 1:61-69.
27. Stuss DT, Benson DF, (1986) The frontal lobes. New York: McGraw Hill.
28. Szabadi E, Bradshaw CM, Besson JA (1976) Elongation of pause-time in speech: a simple, objective measure of motor retardation in depression. Br J Psychiatry 129:592-597.
29. Weinberger DR, Berman KF, Zec RF (1986) Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia. I. Regional cerebral blood flow evidence. Arch Gen Psychiatry 43:114-124.
30. Weinberger DR, Aloia MS, Goldberg TE, Berman KF (1994) The frontal lobes and schizophrenia. J Neuropsychiatry Clin Neurosci 6:419-427.
31. Welham J, Stedman T, Clair A (1999) Choosing negative symptom instruments: issues of representation and redundancy. Psychiatry Res 87:47-56.